Pacific Biosciences of California (NASDAQ:PACB) stock had a bullish inflow of $7.06 million worth of trades on uptick and an outflow of $5.74 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.23. The net money flow into the stock was $1.32 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.42 million. An inflow of $0.54 million block trade was recorded on downticks. $0.95 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 1.78 in favor of the bulls. However, Pacific Biosciences of California (NASDAQ:PACB) stock traded down $0.21 , and reached $7.36, a drop of -2.77% over the previous day. On a weekly basis, the stock is -9.47%, over the previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (SVP, Research & Development) of Pacific Biosciences Of California, Inc., Phillips James Michael had sold 20,000 shares worth of $205,800 in a transaction dated April 25, 2016. In this transaction, 20,000 shares were sold at $10.29 per share. Currently the company Insiders own 19.8% of Pacific Biosciences of California shares according to the proxy statements. Institutional Investors own 66.55% of Pacific Biosciences of California shares.
The company shares have rallied 39.93% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $14.00 and the one year low was seen on Sep 30, 2015. The 50-Day Moving Average price is $9.12 and the 200 Day Moving Average price is recorded at $9.76. Pacific Biosciences of California (NASDAQ:PACB): The stock opened at $7.65 on Wednesday but the bulls could not build on the opening and the stock topped out at $7.68 for the day. The stock traded down to $6.79 during the day, due to lack of any buying support eventually closed down at $7.36 with a loss of -2.77% for the day. The stock had closed at $7.57 on the previous day. The total traded volume was 5,220,460 shares.
Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.